However, monoclonal antibody denosumab neutralizing RANKL treatment is not satisfactory in reducing tumour burden (Helo et al., 2012), suggesting that more molecular insights of interplays between prostate cancer cells and osteoclasts in metastatic niche need to be clarified. Here, TNFSF11 is linked to prostate cancer.